InsiderPulse
Dashboard

HALO

Halozyme Therapeutics, Inc.

Health CareRussell 2000

Halozyme Therapeutics, Inc. insider trading

Halozyme Therapeutics, Inc. files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in San Diego, CA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent HALO insider transactions

3 insiders traded HALO on the open market between Jul 08, 2026 and Sep 16, 2026 — 24 sales worth $15M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$15M

24 of 24 on a 10b5-1 plan

Net
−$15M
Insiders
3

Open-market purchases (code P) and sales (code S) from Halozyme Therapeutics, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every HALO Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

HALO insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 8 insiders traded HALO on the open market: 0 purchases and 154 sales worth $62.8M, 147 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 103 sales ($44.1M), by 5 insiders.

QuarterBoughtSold
Q2 2026—−$10.8M30 sales · all on a plan
Q1 2026—−$9.4M18 sales · 15 on a plan
Q4 2025—−$10.2M28 sales · 27 on a plan
Q3 2025—−$13.6M27 sales · all on a plan
Q2 2025—−$3.5M7 sales · all on a plan
Q1 2025—−$2.3M11 sales · all on a plan
Q4 2024—−$2.1M8 sales · all on a plan
Q3 2024—−$10.7M25 sales · 22 on a plan
Largest sale
−$1.4M of HALO by Torley Helen (President And CEO · Director) on Nov 10, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Krishnan Mahesh10b5-1

    Director

    −$547.8K

    Jun 29, 2026

    7,304 sh · $75.00

  • Torley Helen10b5-1

    President And CEO · Director

    −$425.1K

    Jun 03, 2026

    6,100 sh · $69.69

  • Torley Helen10b5-1

    President And CEO · Director

    −$137.5K

    Jun 03, 2026

    2,000 sh · $68.74

  • Torley Helen10b5-1

    President And CEO · Director

    −$101.5K

    Jun 03, 2026

    1,500 sh · $67.68

  • Torley Helen10b5-1

    President And CEO · Director

    −$26.5K

    Jun 03, 2026

    400 sh · $66.37

  • Torley Helen10b5-1

    President And CEO · Director

    −$1.1M

    Jun 02, 2026

    16,600 sh · $66.31

  • Torley Helen10b5-1

    President And CEO · Director

    −$227K

    Jun 02, 2026

    3,400 sh · $66.75

  • Torley Helen10b5-1

    President And CEO · Director

    −$875.6K

    Jun 01, 2026

    12,989 sh · $67.41

  • Torley Helen10b5-1

    President And CEO · Director

    −$369.2K

    Jun 01, 2026

    5,401 sh · $68.35

  • Connaughton Bernadette10b5-1

    Director

    −$107.6K

    Jun 01, 2026

    1,625 sh · $66.21

  • Torley Helen10b5-1

    President And CEO · Director

    −$106.9K

    Jun 01, 2026

    1,610 sh · $66.39

  • Torley Helen10b5-1

    President And CEO · Director

    −$275.7K

    May 13, 2026

    3,950 sh · $69.79

  • Torley Helen10b5-1

    President And CEO · Director

    −$230.7K

    May 13, 2026

    3,350 sh · $68.88

  • Torley Helen10b5-1

    President And CEO · Director

    −$143K

    May 13, 2026

    2,100 sh · $68.10

  • Torley Helen10b5-1

    President And CEO · Director

    −$42.5K

    May 13, 2026

    600 sh · $70.81

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Halozyme Therapeutics, Inc. company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
San Diego, CA
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001159036
Previously filed as
GLOBAL YACHT SERVICES INC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought HALO

What the stock actually did in the 90 days following each open-market purchase

Don't check HALO — let it ping you

Get told the moment an insider moves on HALO

Pro watches Halozyme Therapeutics, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add HALO to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track HALO on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read HALO insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

EXASNTRACRSPNTLABEAMRXRXTWSTPACBARWRIONSAXSMKRYS
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are HALO insiders buying or selling?
Between Jul 08, 2026 and Sep 16, 2026, 3 Halozyme Therapeutics, Inc. insiders made no open-market purchases and 24 sales worth $15M, a net sale of $15M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much HALO stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 8 Halozyme Therapeutics, Inc. insiders made no open-market purchases and 154 sales worth $62.8M. 147 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 103 sales ($44.1M). The largest sale was Torley Helen selling $1.4M on Nov 10, 2025.
What was the largest recent HALO insider trade?
Torley Helen (President And CEO · Director) sold $1.7M of HALO stock on Sep 11, 2026 at about $107.15 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy HALO shares?
No open-market purchase by a Halozyme Therapeutics, Inc. insider appears in the filings from Jul 08, 2026 to Sep 16, 2026 — every recorded open-market transaction in that period was a sale.
Where does HALO insider trading data come from?
From the Form 4 filings Halozyme Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.